Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Eterna Therapeutics Inc (ERNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -63.63% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.11M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 269126 | Beta 7.33 | 52 Weeks Range 0.16 - 2.63 | Updated Date 03/30/2025 |
52 Weeks Range 0.16 - 2.63 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.26 |
Earnings Date
Report Date 2025-03-12 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -269700% |
Management Effectiveness
Return on Assets (TTM) -39.64% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8067515 | Price to Sales(TTM) 15.66 |
Enterprise Value 8067515 | Price to Sales(TTM) 15.66 | ||
Enterprise Value to Revenue 13.86 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 52244900 | Shares Floating 16745022 |
Shares Outstanding 52244900 | Shares Floating 16745022 | ||
Percent Insiders 74.94 | Percent Institutions 1.9 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. is a biotechnology company focused on developing mRNA-based therapeutics. Details on its founding year and early milestones are not readily available. It evolved from an emphasis on DNA-based therapies to now specialize in mRNA and cell-based therapies. Further research is required to ascertain its complete founding history and evolution.
Core Business Areas
- mRNA Therapeutics: Develops and manufactures messenger RNA (mRNA) therapeutics for various diseases.
- Cell-Based Therapies: Investigates and develops cell-based therapies for specific therapeutic applications.
- Platform Technologies: Focuses on improving mRNA delivery and expression technologies.
Leadership and Structure
Details on the specific leadership team and organizational structure require further research. Information is not readily accessible.
Top Products and Market Share
Key Offerings
- mRNA Therapeutics Pipeline: Developing several mRNA-based therapies for various diseases. Specifics on market share are not currently available. Competitors include Moderna (MRNA) and BioNTech (BNTX).
- Cell-Based Therapy Programs: Developing cell-based therapies for various applications. Specifics on revenue or market share are not currently available. Competitors include Gilead (GILD) with its CAR-T cell therapy programs.
Market Dynamics
Industry Overview
The mRNA therapeutics and cell-based therapy industries are experiencing rapid growth, driven by technological advancements and increased investment in drug development.
Positioning
Eterna Therapeutics is positioned as a developing player in the mRNA and cell therapy space, focusing on innovative approaches. Competitive advantages may include proprietary delivery technologies, if they exist.
Total Addressable Market (TAM)
The total addressable market for mRNA therapeutics and cell-based therapies is estimated to be billions of dollars. Eterna's position within this TAM is determined by the success of their pipeline and commercialization efforts.
Upturn SWOT Analysis
Strengths
- Strong focus on mRNA and cell-based therapies
- Innovative technology platforms (if any)
- Potential for high-value therapeutics
Weaknesses
- Early stage of development
- Limited commercialized products
- Requires significant capital investment for R&D
- Lack of financial data for comprehensive analysis
Opportunities
- Strategic partnerships and collaborations
- Expansion of pipeline through new indications
- Advancements in delivery technologies
- Growing market demand for personalized medicine
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and approval timelines
- Clinical trial failures
- Intellectual property disputes
- Unavailability of public data for further financial analysis
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- GILD
Competitive Landscape
Eterna faces strong competition from established players with greater resources and approved products. Success depends on its ability to differentiate through innovative technology and clinical trial success.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Data on historical growth trends is unavailable.
Future Projections: Future growth projections based on analyst estimates are unavailable.
Recent Initiatives: Recent initiatives might include pipeline expansion, partnerships, or technology advancements, but specific details are not readily available.
Summary
Eterna Therapeutics is an early-stage biotechnology company focused on mRNA and cell-based therapies. It shows promise with its innovative technology platforms, but faces significant challenges related to commercialization, competition, and financial resources. The company's success hinges on successful clinical trials and securing strategic partnerships to advance its pipeline. Further financial data is needed for a comprehensive investment analysis.
Similar Companies
- MRNA
- BNTX
- CRSP
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Limited financial news sources
- SEC filings (if available)
Disclaimers:
The information provided is based on limited publicly available data and should not be considered financial advice. This analysis is for informational purposes only and does not constitute a recommendation to buy or sell any stock. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://eternatx.com |
Full time employees 6 | Website https://eternatx.com | ||
Ernexa Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.